Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Epigenetics

Background:

• Recent advances in understanding melanoma molecular pathogenesis and novel therapies like targeted therapy and immunotherapy have extended survival for advanced melanoma patients.
• However, a significant challenge remains as most patients experience relapse and develop therapeutic resistance over time.
• Cellular plasticity, driven by epigenetic mechanisms, is a key factor in melanoma's therapeutic resistance.

Purpose of the Study:

• To review epigenetic alterations in melanoma development, progression, and resistance to therapy.
• To examine current and developing epigenetic therapies for melanoma and other cancers.
• To provide a framework for future epigenetic therapy advancements to combat melanoma resistance.

Main Methods:

• Literature review of epigenetic alterations in melanoma.
• Analysis of current epigenetic therapies in clinical use and development.
• Assessment of epigenetic therapies in clinical trials for melanoma.

Main Results:

• Melanoma development, progression, and resistance are characterized by specific epigenetic alterations.
• Epigenetic therapies are emerging as a viable strategy to overcome treatment resistance in melanoma.
• A review of ongoing clinical trials highlights the potential of epigenetic interventions.

Conclusions:

• Targeting the epigenetic landscape of melanoma is a crucial strategy to ensure durable treatment responses and potential cures.
• Further research into epigenetic mechanisms and therapies is essential to overcome therapeutic resistance in melanoma.
• Developing novel epigenetic therapies holds promise for improving long-term outcomes for melanoma patients.